Related Experiment Videos
Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory
J H Segars1, M S Marks, S Hirschfeld
1Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, Bethesda, Maryland 20892.
Abstract:
The retinoid X receptor beta (RXR beta; H-2RIIBP) forms heterodimers with various nuclear hormone receptors and binds multiple hormone response elements, including the estrogen response element (ERE). In this report, we show that endogenous RXR beta contributes to ERE binding activity in nuclear extracts of the human breast cancer cell line MCF-7. To define a possible regulatory role of RXR beta regarding estrogen-responsive transcription in breast cancer cells, RXR beta and a reporter gene driven by the vitellogenin A2 ERE were transfected into estrogen-treated MCF-7 cells. RXR beta inhibited ERE-driven reporter activity in a dose-dependent and element-specific fashion. This inhibition occurred in the absence of the RXR ligand 9-cis retinoic acid. The RXR beta-induced inhibition was specific for estrogen receptor (ER)-mediated ERE activation because inhibition was observed in ER-negative MDA-MB-231 cells only following transfection of the estrogen-activated ER. No inhibition of the basal reporter activity was observed. The inhibition was not caused by simple competition of RXR beta with the ER for ERE binding, since deletion mutants retaining DNA binding activity but lacking the N-terminal or C-terminal domain failed to inhibit reporter activity. In addition, cross-linking studies indicated the presence of an auxiliary nuclear factor present in MCF-7 cells that contributed to RXR beta binding of the ERE. Studies using known heterodimerization partners of RXR beta confirmed that RXR beta/triiodothyronine receptor alpha heterodimers avidly bind the ERE but revealed the existence of another triiodothyronine-independent pathway of ERE inhibition. These results indicate that estrogen-responsive genes may be negatively regulated by RXR beta through two distinct pathways.
Insights
Retinoid X receptor beta (RXR beta) negatively regulates estrogen-responsive genes in breast cancer cells. RXR beta inhibits estrogen receptor activity through distinct pathways, offering new therapeutic targets.
Area of Science:
- Molecular Biology
- Endocrinology
- Cancer Research
Background:
- Retinoid X receptor beta (RXR beta) is a nuclear receptor that heterodimerizes with other nuclear receptors.
- RXR beta binds to hormone response elements, including the estrogen response element (ERE).
- The role of RXR beta in estrogen-responsive transcription in breast cancer remains to be fully elucidated.
Purpose of the Study:
- To investigate the regulatory role of RXR beta in estrogen-responsive transcription in breast cancer cells.
- To determine the mechanism by which RXR beta affects estrogen receptor (ER)-mediated ERE activation.
Main Methods:
- Transfection of RXR beta and a reporter gene into MCF-7 and MDA-MB-231 breast cancer cell lines.
- Treatment with estrogen and/or RXR ligands.
- Reporter gene activity assays.
- Analysis of DNA-binding activity using deletion mutants and cross-linking studies.
Main Results:
- Endogenous RXR beta contributes to ERE binding activity in MCF-7 cells.
- RXR beta inhibited ERE-driven reporter activity in a dose-dependent and element-specific manner.
- Inhibition occurred independently of RXR ligands and was specific to ER-mediated activation.
- RXR beta/triiodothyronine receptor alpha heterodimers bind ERE, but another triiodothyronine-independent inhibition pathway exists.
Conclusions:
- RXR beta negatively regulates estrogen-responsive genes in breast cancer cells.
- RXR beta employs at least two distinct pathways to inhibit ER-mediated transcription.
- These findings suggest RXR beta as a potential therapeutic target for breast cancer.